Pharmacology

Giving a neuromuscular blocking agent early in ARDS may improve survival

According to a study in the New England Journal of Medicine, administering a neuromuscular blocking agent for 48 hours at the onset of severe Adult Respiratory Distress Syndrome (ARDS) improved patient survival at 90 days without worsening muscle weakness. Read more here.


Related Articles:

Leave a Reply

Your email address will not be published. Required fields are marked *

 

Shares